QLH 11811
Alternative Names: QLH-11811Latest Information Update: 13 Apr 2023
At a glance
- Originator Qilu Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 25 Oct 2022 Phase-I clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO) (NCT05555212)
- 25 Oct 2022 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent, Inoperable/Unresectable) in China (PO) (NCT05555212)
- 26 Sep 2022 Qilu Pharmaceutical plans a phase I trial for Non-small cell lung cancer (PO, Late-stage disease, Second line therapy, Metastatic disease) in China in September 2022(NCT05555212)